Major US Distributor announced!
I'm on 20 min delay, so I don't know details, but might be good for a quick trade for you guys
Major US Distributor announced!
I'm on 20 min delay, so I don't know details, but might be good for a quick trade for you guys
Visiomed Secures Major UK Distributor for Funhaler®Initial commitment of 112,000 units during first 2 Years
Agency arrangements include Boots Chemists and Lloyds Pharmacy distribution Contract lifts total committed sales for Funhaler over next 2 years to $6MPlacement to raise $1 million to support international marketing efforts.Visiomed Group Ltd (ASX: VSG) has signed an initial 2-Year Agreement with major
UK medical distributor Clinisupplies Ltd to supply its innovative Funhaler® paediatric incentive asthma spacer throughout major retail pharmacy outlets including Boots
and Lloyds, two of the UK's largest pharmacy chains. Secures Major UK Distributor. The Agreement will see Visiomed supply UK pharmacies
with an initial 32,000 units during Year 1 of the contract and 80,000 units during Year 2,
commencing mid 2007.
Visiomed Chief Executive Officer Dr William Dolphin said: "During the last Quarter we have expanded our distribution network significantly, signing on leading distributors in major
overseas markets including the US and Europe.
"With the addition of Clinisupplies for the UK we now have in excess of US$6 million in
committed sales for the Funhaler in overseas markets during the next 2 years; this is in
addition to strong revenues from the Funhaler and Breath-A-Tech spacers in Australia
where Visiomed is the market-leading spacer manufacturer, and from royalties generated
through our licensing agreement with US-based Respironics."
According to a recent report from the Global Initiative for Asthma (GINA), the UK has one of
the highest prevalence of asthma in the world, with the condition afflicting an estimated
18.4% of the population.
"Presenting the Funhaler®to the major UK market via globally recognised pharmacies like Boots and Lloyds is a significant achievement for Visiomed. With a population of
approximately 61 million and an extremely high prevalence of asthma, the UK is an
important and influential market within the European Community," Dr Dolphin said. "We are
very pleased to be working with a group having the outstanding sales history and healthcare
market penetration of Clinisupplies."
The contract pricing with Clinisupplies, whilst agreed, is conditional upon approval of
proposed pricing by the UK National Health Service Business Services Authority. An application in this regard has been lodged with the BSA by the Company. In the unlikely
event proposed pricing is not approved the contract pricing terms may have to be amended. CliniSupplies is expected to commence UK product sales in mid-2007, assuming Visiomed's
NHS BSA application is successful.
The Funhaler®is already CE Marked and has required regulatory approvals for sale into Europe and the UK.
Placement to Raise $1 Million. The Company is pleased to confirm a Placement of 60
million shares at 1.7 cents to sophisticated investors. The Placement will raise
approximately AU$1 million (net of costs) and includes 1:3 attaching unlisted options at 2.5 cents expiring in 18 months. Following the Placement the Company will have cash and
cash equivalents of approximately AU$2.4 million. The funds raised will supplement existing working capital and will be applied primarily to the expansion of overseas distribution of the
Funhaler®asthma spacer into the USA and European markets.
see... I told you I live in hope
Lets keep fingers crossed that this will help boost this one a little
VSG is starting to become a solid little stock.
Great rises over the last couple of days nice move through 2cps
Volume is picking up as well.
Srong crossover MACD
It's either one of three things;
1: Takeover by larger company
2: New distributor (UK, Japan)
3: A distributor reordering (US, EU)
My first Chart - baby steps, Sam, baby steps...
Can someone more experienced tell me what they see from the chart. ta.
Hey there Sam
Still hanging in there huh??? well, so am I
Very much doubt there is a takeover (but then again I have been known to be wrong before)
Let's just hope it continues....
I'm no chart genius, but surely this is one very nice chart. There's movement at the station, the director is buying into the stock, the company is appointing distributors...
be warned; even my dog ignores me
yes the director is buying up - another ann. this afternoon - lets hope he knows something that we don't coz I've been hanging in there (by a very short rope) for a long time....
Last edited by surelle; 20th-June-2007 at 03:44 PM. Reason: typo
How good is it to see someone else on this board?
VSG up 42% in the last 20 days.
yes it's great to see a newcomer - excuse my poor manners moses - welcome
how good has June been to VSG for a change and there's been some good vol today - 12mill.
someone's interested in this one this morning....but who's complaining - not me
Sam what do you think??
Sorry been with clients all morning.
Something is definately up with with VSG.
what it is I don't know, but I'm glad I held on over the years. My holding is up over 70% now. (I'm glad I averaged down!)
What's your strategy for these? Are you sticking with them or taking profits?
I'm holding on as I think there is a lot more good things to come.
either way, we deserve a bit of love for holding on!!
I thought that i would mention that their was a small breakout yesterday with 80 million shares traded.this was due to an announcement relating to a Chinese patent that was granted.(“Improved drug delivery device).I assume that the volume will increase today maybe not as high as nal but it certainly has a better financial position then NAL. And looking at the charts i suspect that it could be included as a potential breakout.IMO
Anyway i will be closely watching today as i have a small parcel.Good luck all.
Hi Uranium, you're new to this thread -welcome to the new blood
Sam, sorry didn't see your reply
yes, finally some good news - lets hope that this will help them make a BIG push into the Chinese market - I am still holding these babies coz I still think they have potential to grow and they are certainly showing proactive development.
But then, I have been known to be wrong in the past
Hey sam, you still holding???
Last edited by surelle; 13th-September-2007 at 07:38 AM. Reason: additional text
Yep, I'm still here and watching VSG closely.
Some nice heavy buying this afternoon after Wednesday's dump.
I've been buying on weakness as the worst is now behind us.
The China announcement really put VSG on the radar for a lot of people out there. Unfortunately a few day traders got caught earlier on in the month when she rose 50% in a couple of hours. The sell side will be gone on the next positive announcement (which will most likely be the quartely).
I picked up a few of the oppies as well for a punt.
too funny, we live in hope heh?
I can't wait for them to do some dancing and start moving
I'll keep on hoping for both of us
Announcement out Thursday.
I'm expecting it to be distributor agreements with either Japan or Germany (or at least positive news)
VSG have traditionally gone into a halt for large-scale agreements (uk and US)
Hey there Sam
I think you're right, they have, in the past, halted for a distributor ann.
I've even got the toes crossed on this one (not just the fingers).
Onwards and upwards I always say
Not sure how to take this at the moment, but hopefully we do alright out of it.
Deliver, Comply and Monitor
10 October 2007
VISIOMED GROUP AND CLINICAL CELL CULTURE
Visiomed Group Limited (Visiomed, ASX: VSG) and Clinical Cell Culture Ltd (C3,
ASX: CCE) today announced a merger proposal by way of schemes of arrangement
under which C3 will make offers to acquire all of the issued securities in Visiomed.
Under the terms of the proposed schemes of arrangement ("Schemes"), Visiomed
shareholders will receive 5 C3 shares for every 7 Visiomed shares held. Holders of
Visiomed listed options will receive 5 new C3 options for every 7 listed Visiomed
options they hold.
In addition to the Visiomed listed options, Visiomed has unlisted options which will be
dealt with via individual conditional agreements.
Upon completion of the merger, Visiomed shareholders will own approximately 53% of
the expanded company and C3 shareholders will own approximately 47%.
The schemes of arrangement will be subject to conditions including:
• satisfactory completion of due diligence by the Boards of both companies;
• Visiomed security holder approvals and court approvals in respect of the
• all relevant regulatory approvals; and
• other conditions customary for a public transaction of this nature.
Visiomed and C3 have entered into a Merger Implementation Agreement and the
parties have agreed to share all of the costs of the merger and implementation of the
Visiomed CEO Dr Bill Dolphin said the merger represented an outstanding opportunity
for the Company’s shareholders.
“C3’s offer provides Visiomed the opportunity to extend our product portfolio and fast
track the expansion of our flagship Funhaler® and Breath-A-Tech asthma spacer
products into international markets,” said Dr Dolphin.
“C3 is based in the UK, has significant experience in the medical device arena, a
thorough understanding of the European market and a comprehensive infrastructure
and sales network already in place – all of which will be of enormous immediate benefit
to Visiomed’s sales and marketing efforts in the region. In turn, C3 will benefit from
Visiomed’s existing product revenue stream, our presence in and familiarity with the US
medical market, and our knowledge and experience in working with the US FDA
Dr Dolphin said that given C3’s strong cash position, the merger would also provide
Visiomed with added financial capability to support further profitable growth.
“This merger is in line with our stated strategy of pursuing partnerships and strategic
alliances with companies that operate in the medical device space and that provide
Visiomed with the ability to grow the business on an international scale,” he said.
“We are excited at the prospect of merging our business with C3 and believe the offer
provides an excellent opportunity for Visiomed shareholders to maximise the value of
their investment while also becoming part of a larger, more progressive biomedical
C3 Chief Executive Officer Andrew Cannon said the merger of the two organisations
would create a medical device group with increasing revenue and a strong cash
position – placing both companies in a stronger position for growth.
“This is a merger of two similar medical device companies – C3 a producer of tissueengineered
products and Visiomed a producer of respiratory devices,” said Mr Cannon.
“The strategy is to create a stronger, more financially robust company and a stronger
balance sheet, better cashflows and a more attractive investment for shareholders of
Mr Cannon said C3 believed there was enormous potential for Visiomed’s asthma
“There are distribution agreements already in place throughout North America, Europe,
the Middle East and Australasia. As well as diversifying our existing product range, the
merger will provide C3 with access to additional product revenue streams generated
through product sales in Europe and Asia and ahead of FDA approval of ReCell® for
the US market,” he said.
“We remain committed to the commercialisation of ReCell® and are focused on
securing FDA approval for sale of the product in the US.
“However, as we explained at the time of our strategic review in March 2007, we are
also committed to ensuring the company’s cash resources are focused on maximising
returns for shareholders and we believe merging with Visiomed is in line with that
“We see this merger as very much a win-win situation for both companies and their
Benefits to Visiomed shareholders
• Balance sheet to support the implementation of the company’s expansion
• Infrastructure in UK and Europe to provide support for the commercialisation of
spacer products: Funhaler® and Breath-A-Tech
• Access to understanding and knowledge of the European biotech market
• Larger scale and greater geographic diversification
• Scale and synergy benefits
Benefits to C3 shareholders
• Builds revenue base
• Immediate access to product revenue streams
• Diversifies C3 range of medical devices
• Leverages C3’s existing European markets infrastructure
• Access to understanding and knowledge of the US biotech market and
• Improved value proposition
• Diversified shareholder base
The merged entity will be headquartered at C3’s existing head office location in
Cambridge, UK. Both companies will continue to trade under their existing business
names until completion of the merger and while consideration is given to determining
branding for the long term.
It is envisaged that both companies will be equally represented at Board level and the
current executive directors will share responsibilities.
A transaction timetable will be provided to shareholders in due course.
The C3 shares to be issued as scheme consideration will rank equally with other
issued C3 shares and the C3 options will be listed and have an expiry date of 30 March
2008 and exercise price of 24 cents.
C3 and Visiomed security holders do not need to take any action at this time.
Visiomed security holders will be provided with a Scheme Booklet in due course
outlining the proposal in greater detail.
Key steps to be undertaken include:
• lodgement of Scheme documents with ASIC;
• obtaining Court approval to hold the Scheme meetings for security holders to
vote on the Schemes;
• obtaining Visiomed security holders approval for the Schemes; and
• if Visiomed security holders approve the Schemes, Court ratification of the
FOR FURTHER INFORMATION PLEASE CONTACT:
Andrew Cannon John McGlue
Clinical Cell Culture Porter Novelli
Tel: +44 (0) 1223 341 150 Tel: +61 (0) 8 9386 1233
Email: [email protected] Mob: +61 (0) 417 926 915
Bill Dolphin Sarah Allchurch
Visiomed Group Allchurch Communications
Tel: +61 (0)8 9389 0700 Tel: +61 (0) 8 9381 6625
Email: [email protected] Mob: +61 (0) 412 346 412
About Visiomed Group Ltd
Visiomed Group (ASX: VSG) develops and commercialises innovative medical
technologies for improved medication delivery and adherence in patients suffering from
chronic respiratory diseases, providing the interface between patient and their medication.
Visiomed manufactures and sells a range of spacers for the paediatric, adolescent and
adult market and is the leading provider of spacers in Australia. More than 350 million
people suffer from asthma and COPD (chronic obstructive pulmonary disorder, including
chronic bronchitis and emphysema) and are candidates for the company’s spacer products.
The Funhaler® paediatric incentive spacer and Breath-A-Tech spacer products are covered
by international patents issued and pending. The coverage extends to protection of a wide
range of alternative incentive modules and complimentary applications. The Funhaler® is
CE marked for the EU, FDA cleared for the US and TGA registered in Australia.
About Clinical Cell Culture
Clinical Cell Culture (C3, ASX: CCE) is a publicly listed biomedical company that develops
and distributes tissue-engineered products for the treatment of wounds and other skin
defects. Using proprietary tissue-culture/ collection technology, C3 is able to provide
innovative treatment solutions derived from the patients own skin, to enhance healing rates,
reduce scar formation and reintroduce pigmentation into the skin.
Its flagship product, ReCell® (www.recell.info) is a stand-alone, rapid cell harvesting device
that enables surgeons to treat skin defects using the patient’s own cells that are collected
during surgery. The surgeon can prepare a small quantity of cells within 30 minutes on site
rather than having to send a biopsy to the laboratory. ReCell® has been designed for use in
a wide variety of plastic, reconstructive and cosmetic procedures.
ReCell® is approved for sale in Australia, Brazil, Canada, Chile, Croatia, European Union,
Hong Kong, Israel, Japan, Malaysia, New Zealand, Norway, Singapore, South Africa,
Switzerland and Turkey. The company is currently focused on securing FDA approval for
sale of the product in the USA.
I think we have to hope CCE prices rise because they now determine the price of VSG
ie. CCE is currently at 0.035
that means VSG is currently worth 0.025 or = 0.035/7 * 5, at time of merger